Abstract:Pancreatic cancer is one of the most lethal malignancies worldwide, it often results in therapeutic failure and unfavorable outcome because of the absence of screening strategies, difficulties in tumor early detection due to the lack of specific signs/symptoms and aggressive behavior of the disease. Early detection of this cancer is a challenge with the technology we have, its late detection results in a poor outcome and reduced quality of life for the patient. The treatment success depends on surgical intervention, which is not always possible. Thus, trying to find alterations that occur in the early stages of pancreatic cancer is needed. Taking into consideration that the accumulation of genetic and epigenetic alterations results in a complex and heterogeneous disease, each patient has a unique tumor. The heterogeneity of cancer is not restricted to inter-patient differences but, intra-tumoral heterogeneity contributes to functional properties of tumor cell subclones, including proliferative capacity and progression to aggressive phenotypes such as drug tolerance and metastatic potential. Driver mutations are responsible for malignant transformation and tumor progression across different cancer types. One of the most common driver mutations are those leading to the constitutive activation of KRAS oncogene, a GTPase enzyme responsible for cell proliferation and survival that is frequently mutated in pancreatic cancer. Gain-of-function mutation of KRAS gene leads to a protein constitutively activated, which stimulates the proliferation of tumor cells. The c.34G>T missense mutation (rs121913530) causes the substitution of glycine for cysteine in the encoded protein KRASG12C; this mutation has been related to poorer prognosis and therapy resistance in lung cancer. As KRAS occurs before the progression of pancreatic cancer to invasive carcinoma, it is a promising target for new biomarker development. We design three near-infrared probe-drug conjugate directed to the KRASG12C and to predict in silico the best orientation and conformation of the test compounds bound to the KRAS G12C (PDB code: 6OIM), the PyRx program was used, which uses AutoDock Vina as docking software. Based on these profiles and structures of the compounds, AutoDock Vina infers the possible pharmacological interactions and allows the most promising compounds to be classified according to the studied biological activity, using the empirical score function for this classification. The AMG 510 (established inhibitor) and GDP (endogenous activator) were used as a reference to establish the docking box coordinates. The binding energy of the three compounds predicted by docking was analyzed and classified according to the binding affinity described in Kcal/mol. The tested compounds show an excellent affinity for this protein based on the binding energy results obtained by docking using the crystallized KRAS G12C protein. Therefore, they could be great candidates for further chemical synthesis studies aiming to improve diagnosis, treatment, and patient survival in pancreatic cancer. Citation Format: Barbara M. Barbosa, Allana C. F. Martins, Roberto S. Gomes, Claudia A. Rainho. In silico drug design using KRASG12C as a theranostic target for pancreatic cancer [abstract]. In: Proceedings of the AACR Special Conference on Pancreatic Cancer; 2022 Sep 13-16; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2022;82(22 Suppl) nr B040.

Nanotechnology-assisted intracellular delivery of antibody as a precision therapy approach for KRAS-driven tumors

TCR-mimic Antibody-Drug Conjugates Targeting Intracellular Tumor-Specific Mutant Antigen KRAS G12V Mutation

Abstract 6717: Targeting mutant KRAS proteins with novel TCR-mimic fully human antibodies

Development of A Novel RON Targeted Antibody‐Drug Conjugates Using Cysteine Bridging Technology for Potential Treatment of Pancreatic Cancer

Targeted degradation of KRAS protein in non-small cell lung cancer: Therapeutic strategies using liposomal PROTACs with enhanced cellular uptake and pharmacokinetic profiles

Targeted nanoconjugate co-delivering siRNA and tyrosine kinase inhibitor to KRAS mutant NSCLC dissociates GAB1-SHP2 post oncogene knockdown

Intracellular KRAS-specific antibody enhances the anti-tumor efficacy of gemcitabine in pancreatic cancer by inducing endosomal escape

Controlled coupling of an ultrapotent auristatin warhead to cetuximab yields a next-generation antibody-drug conjugate for EGFR-targeted therapy of KRAS mutant pancreatic cancer

Targeted nanodelivery of siRNA against KRAS G12D inhibits pancreatic cancer

[Preclinical Study of T Cell Receptor Specifically Reactive with KRAS G12V Mutation in the Treatment of Malignant Tumors].

Abstract B040: In silico drug design using KRASG12C as a theranostic target for pancreatic cancer

KRAS-enhanced Macropinocytosis and Reduced FcRn-mediated Recycling Sensitize Pancreatic Cancer to Albumin-Conjugated Drugs

Ionizable lipid nanoparticles for RAS protease delivery to inhibit cancer cell proliferation

Novel druggable space in human KRAS G13D discovered using structural bioinformatics and a P-loop targeting monoclonal antibody

Targeted siRNA nanocarrier: a platform technology for cancer treatment

Abstract 1127: Preclinical development of safe and effective T cell receptors specific for mutant KRAS G12D peptide

Abstract 569: BIO-PROTAC: New treatment modality to treat undruggable KRAS mutants by application of cell penetrating scFv

Abstract 4060: Discovery and preclinical development of KRAS-targeting siRNA therapeutic modality for the treatment of pancreatic cancer

Abstract 1216: Pan-RAS inhibition by a tumor-targeted biotherapeutic

Targeting KRASG12V mutations with HLA class II-restricted TCR for the immunotherapy in solid tumors

Nano-engineered monoclonal antibodies expanding the newer avenues for cancer targeting